Recombinant Human Renalase Protein, CF

R&D Systems | Catalog # 9887-RE

R&D Systems
100% Guarantee

Key Product Details

  • R&D Systems E. coli-derived Recombinant Human Renalase Protein (9887-RE)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

E. coli

Accession Number

Q5VYX0-1

Applications

Enzyme Activity
View all Renalase Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human Renalase protein
Ala2-Ile342
with substitution Glu37Asp, N-terminal Met and 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met

Predicted Molecular Mass

39 kDa

SDS-PAGE

39 kDa, reducing conditions

Activity

Measured by its ability to reduce Resazurin.
The specific activity is >3.5 pmol/min/μg, as measured under the described conditions.

Scientific Data Images for Recombinant Human Renalase Protein, CF

Recombinant Human Renalase Protein Enzyme Activity

Recombinant Human Renalase Protein Enzyme Activity

Recombinant Human Renalase (Catalog # 9887-RE) is measured by its ability to reduce Resazurin (Catalog # AR002).

Formulation, Preparation, and Storage

9887-RE
Formulation Supplied as a 0.2 μm filtered solution in Tris, EDTA, DTT and Glycerol.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: Renalase

Renalase has been reported to regulate cardiac function and blood pressure and initially proposed to metabolize ciculating catecholamines (1). Recent characterization has clarified the true enzymatic function of renalase is oxidation of NAD(P)H isomers to B-NAD(P)+ (2, 3). As these molecules are potent inhibitors of primary metabolism dehydrogenases, cellular renalase activity serves to prevent the inhibitory effects of these molecules on primary metabolism (2, 3). Renalase was initially found to have robust expression in the kidney (1) and later confirmed to have systemic expression in all tissues. Renalase is classified as a member of the flavoprotein superfamily but uniquely lacks an internal structural element that causes its active site to be solvent exposed (4). Renalase contains a putative secretory N-terminal signal sequence (aa 1-17) that also contains residues required for FAD cofactor binding, suggesting that the enzyme would require the N-terminus to remain functionally active (3). However, renalase is found both intracellularly and secreted extracellularly. Extracellular renalase is cleaved during secretion from the cell (5). Circulating renalase acts as a cytokine, resulting in extensive reported physiological effects (6). Increases in blood pressure was induced by renalase gene knockout (7) and gene deletion aggravates acute ischemic kidney (8). Polymorphisms in renalase are associated with hypertension and stroke in type 2 diabetes (9, 10). Full-length recombinant renalase as well as truncated, non-active, peptides were found to promote cell and organ survival in a process independent of enzymatic activity via signaling through the receptor PMCA4b, characterized as an ATPase involved in cell signaling and cardiac hypertrophy (11, 12). Renalase was significantly increased in pancreatic, bladder, breast and melanoma cancers where its signaling role favors cell survival and tumor growth (13). Consequently, renalase inhibition has been suggested to provide a novel therapeutic option for cancer treatment (13).

References

  1. Xu, J. et al. (2005) J. Clin. Invest. 115:1275.
  2. Beaupre, B. A. et al. (2015) Biochemistry 54:795.
  3. Moran, G.R. et al. (2016) Biochim. Biophys. Acta 1864:177.
  4. Milani, M. et al. (2011) J. Mol. Biol. 411:463.
  5. Fedchenko, V. et al. (2016) Kidney Blood Press. Res. 41:593.
  6. Guo, X. et al. (2014) Curr. Opin. Nephrol. Hypertens. 23:513.
  7. Wu, Y. et al. (2011) Kidney International 79:853.
  8. Lee, H.T. et al. (2013) J. Am. Soc. Nephrol. 24:445.
  9. Buraczynska, M. et al. (2011) Neuromolecular Med. 13:321.
  10. Orlowska-Baranowska, E. et al. (2017) PLoS One 125:e0186729.
  11. Wang, L. et al. (2015) PLoS ONE 10:e0122932.
  12. Wang, L. et al. (2014) J. Am. Soc. Nephrol. 25:1226.
  13. Wang, Y. et al. (2017) J. Cell. Mol. Med. 21:1260.

Alternate Names

C10orf59, RNLS

Entrez Gene IDs

55328 (Human); 67795 (Mouse); 361751 (Rat)

Gene Symbol

RNLS

UniProt

Q5VYX0-1

Additional Renalase Products

Product Documents for Recombinant Human Renalase Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human Renalase Protein, CF

For research use only

Related Research Areas

Oxidases and Oxygenases
Redox Enzymes

Customer Reviews for Recombinant Human Renalase Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human Renalase Protein, CF and earn rewards!

Have you used Recombinant Human Renalase Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

View specific protocols for Recombinant Human Renalase Protein, CF (9887-RE):

Materials
  • Assay Buffer: 50 mM HEPES, 200 mM NaCl, 5 µM FAD (Flavin Adenine Dinucleotide), 0.05% Tween-20, pH 7.5
  • Recombinant Human Renalase (rhRenalase) (Catalog # 9887-RE)
  • beta -Nicotinamide adenine dinucleotide, reduced (NADH) (Sigma, Catalog # N8129), 20 mM stock in 0.1 M Sodium Borate, pH 9.0
  • Resazurin (Catalog # AR002) (MW = 251.17 Da)
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
  1. Dilute rhRenalase to 40 µg/mL in Assay Buffer.
  2. Prepare a Substrate Mixture containing 400 µM of NADH and 20 µM Resazurin in Assay Buffer.  Mix well and use immediately.
  3. Load 50 µL of 40 µg/mL rhRenalase into a plate, and start reaction by adding 50 µL Substrate Mixture.  Include a Substrate Blank containing 50 µL Assay Buffer and 50 µL Substrate Mixture.
  4. Read plate at excitation and emission wavelengths of 540 and 585 nm, respectively, in kinetic mode for five minutes.
  5. Calculate specific activity:
     

     Specific Activity (pmol/min/µg) =

 Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU)
amount of enzyme (µg)

 

*Adjusted for Substrate Blank.
**Derived using calibration standard Resorufin (Sigma, Catalog # R3257).

Per Well:

  • rhRenalase: 2.0 µg
  • NADH: 200 µM
  • Resazurin: 10 µM

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes